The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis

Abstract

Epithelial–mesenchymal transition (EMT) is an essential process in normal embryonic development and tissue regeneration. However, aberrant reactivation of EMT is associated with malignant properties of tumor cells during cancer progression and metastasis, including promoted migration and invasiveness, increased tumor stemness, and enhanced resistance to chemotherapy and immunotherapy. EMT is tightly regulated by a complex network which is orchestrated with several intrinsic and extrinsic factors, including multiple transcription factors, post-translational control, epigenetic modifications, and noncoding RNA-mediated regulation. In this review, we described the molecular mechanisms, signaling pathways, and the stages of tumorigenesis involved in the EMT process and discussed the dynamic non-binary process of EMT and its role in tumor metastasis. Finally, we summarized the challenges of chemotherapy and immunotherapy in EMT and proposed strategies for tumor therapy targeting EMT.

References 314

1. 1.

   Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-273.

   Not in our library10.1038/nrc2620

2. 2.

   Gros J, Tabin CJ. Vertebrate limb bud formation is initiated by localized epithelial-to-mesenchymal transition. Science. 2014;343:1253-1256.

   Not in our library10.1126/science.1248228

3. 3.

   Correa-Costa M, Andrade-Oliveira V, Braga TT, Castoldi A, Aguiar CF, Origassa CS, Rodas AC, Hiyane MI, Malheiros DM, Rios FJ, et al. Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest. 2014;94:455-466.

   Not in our library10.1038/labinvest.2013.155

4. 4.

   Ruscetti M, Quach B, Dadashian EL, Mulholland DJ, Wu H. Tracking and functional characterization of epithelial-mesenchymal transition and mesenchymal tumor cells during prostate cancer metastasis. Can Res. 2015;75:2749-2759.

   Not in our library10.1158/0008-5472.can-14-3476

5. 5.

   Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017;232:3261-3272.

   Not in our library10.1002/jcp.25797

6. 6.

   Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;2016(166):21-45.

   Not in our library10.1016/j.cell.2016.06.028

7. 7.

   Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.

   Not in our library10.1172/jci39104

8. 8.

   Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395-412.

   Not in our library10.1146/annurev-pathol-020117-043854

9. 9.

   Pal A, Barrett TF, Paolini R, Parikh A, Puram SV. Partial EMT in head and neck cancer biology: a spectrum instead of a switch. Oncogene. 2021;40:5049-5065.

   Not in our library10.1038/s41388-021-01868-5

10. 10.

    Cano A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83.

    Not in our library10.1038/35000025

11. 11.

    Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7-13.

    Not in our library10.1016/j.ceb.2016.06.002

12. 12.

    Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166:21-45.

    Not in our library10.1016/j.cell.2016.06.028

13. 13.
    Guidelines and definitions for research on epithelial–mesenchymal transition · 2020

    Corrected
14. 14.

    Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463-468.

    Not in our library10.1038/s41586-018-0040-3

15. 15.
    EMT : Present and future in clinical oncology · 2017

    No notice
16. 16.

    Cai Y, Wang B, Li B, Huang X, Guo H, Liu Y, Chen B, Zhao S, Wu S, Li W, et al. Collection on reports of molecules linked to epithelial-mesenchymal transition in the process of treating metastasizing cancer: a narrative review. Ann Transl Med. 2021;9:946.

    Not in our library10.21037/atm-20-7002

17. 17.

    Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69-84.

    Not in our library10.1038/s41580-018-0080-4

18. 18.

    Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49:361-374.

    Not in our library10.1016/j.devcel.2019.04.010

19. 19.
    Dynamic EMT: a multi‐tool for tumor progression · 2021

    No notice
20. 20.

    Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178-196.

    Not in our library10.1038/nrm3758

21. 21.

    Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.

    Not in our library10.1016/j.cell.2009.11.007

22. 22.

    Nakaya Y, Sheng G. Epithelial to mesenchymal transition during gastrulation: an embryological view. Dev Growth Differ. 2008;50:755-766.

    Not in our library10.1111/j.1440-169x.2008.01070.x

23. 23.

    Axelrod JD. Cell shape in proliferating epithelia: a multifaceted problem. Cell. 2006;126:643-645.

    Not in our library10.1016/j.cell.2006.07.018

24. 24.

    Singh M, Yelle N, Venugopal C, Singh SKEMT. Mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80-94.

    Not in our library10.1016/j.pharmthera.2017.08.009

25. 25.

    Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973-981.

    Not in our library10.1083/jcb.200601018

26. 26.

    Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796:75-90.

    Not in our library10.1016/j.bbcan.2009.03.002

27. 27.

    Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012;139:3471-3486.

    Not in our library10.1242/dev.071209

28. 28.

    Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature. 2010;463:485-492.

    Not in our library10.1038/nature08908

29. 29.

    Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15-33.

    Not in our library10.1007/s10555-008-9169-0

30. 30.

    Huang RY, Guilford P, Thiery JP. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci. 2012;125:4417-4422.

    Not in our library10.1242/jcs.099697

31. 31.

    Williams CM, Engler AJ, Slone RD, Galante LL, Schwarzbauer JE. Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer Res. 2008;68:3185-3192.

    Not in our library10.1158/0008-5472.can-07-2673

32. 32.

    Pasquier J, Abu-Kaoud N, Al Thani H, Rafii A. Epithelial to mesenchymal transition in a clinical perspective. J Oncol. 2015;2015:792182.

    Not in our library10.1155/2015/792182

33. 33.

    Derynck R, Weinberg RA. EMT and cancer: more than meets the eye. Dev Cell. 2019;49:313-316.

    Not in our library10.1016/j.devcel.2019.04.026

34. 34.

    St Johnston D, Ahringer J. Cell polarity in eggs and epithelia: parallels and diversity. Cell. 2010;141:757-774.

    Not in our library10.1016/j.cell.2010.05.011

35. 35.

    Lee M, Vasioukhin V. Cell polarity and cancer–cell and tissue polarity as a non-canonical tumor suppressor. J Cell Sci. 2008;121:1141-1150.

    Not in our library10.1242/jcs.016634

36. 36.

    Nakaya Y, Sheng G. EMT in developmental morphogenesis. Cancer Lett. 2013;341:9-15.

    Not in our library10.1016/j.canlet.2013.02.037

37. 37.

    Weston JA, Thiery JP. Pentimento: neural crest and the origin of mesectoderm. Dev Biol. 2015;401:37-61.

    Not in our library10.1016/j.ydbio.2014.12.035

38. 38.

    Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116:499-511.

    Not in our library10.1242/jcs.00224

39. 39.

    Bax NA, Pijnappels DA, van Oorschot AA, Winter EM, de Vries AA, van Tuyn J, Braun J, Maas S, Schalij MJ, Atsma DE, et al. Epithelial-to-mesenchymal transformation alters electrical conductivity of human epicardial cells. J Cell Mol Med. 2011;15:2675-2683.

    Not in our library10.1111/j.1582-4934.2011.01266.x

40. 40.

    Barsan V, Cristofanilli M, Mani SA. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Breast Dis A Year Book Q. 2013;24:225-226.

    Not in our library10.1016/j.breastdis.2013.07.021

Cited by papers we hold 6

• Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer · 2025
  No notice
• Drug repurposing for cancer therapy · 2024
  No notice
• PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells · 2023
  No notice
• Role of Epithelial to Mesenchymal Transition in Colorectal Cancer · 2023
  No notice
• Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression via Mediating hnRNPK/β-Catenin Complex · 2023
  No notice
• Focal adhesion kinase: from biological functions to therapeutic strategies · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.